Hypercalcemia - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The hypercalcemia market is projected to experience steady growth with a stable Compound Annual Growth Rate (CAGR) from 2025 to 2034, driven by advancements in targeted therapies, increased screening and early diagnosis, rising incidence of malignancies and other underlying conditions, and growing awareness among healthcare providers and patients about the importance of effectively managing elevated calcium levels.
• Hypercalcemia is a common metabolic complication in cancer, occurring in roughly 30% of patients at some point during their illness. The highest occurrence is observed in multiple myeloma, affecting about 7.5% of cases, while prostate cancer shows the lowest rate, at approximately 1.4%.
• Our research indicates that in the US, approximately 2 million new cancer cases occur each year, out of which more than 300,000 cases are breast cancer, 200,000 are lung cancer, and more than 35,000 are myeloma respectively.
• In Italy, approximately 450,000 cancer cases are reported annually, with about 30% of patients developing hypercalcemia.
• In hypercalcemia, the absence of any the US FDA-approved therapy with market exclusivity presents a potential opening for novel treatments, offering scope for emerging drugs to address clinical gaps and establish a competitive foothold in this therapeutic space.
• There remains a significant unmet need in the management of hypercalcemia due to limited epidemiological data, highlighting challenges in accurately understanding disease burden, patient populations, and treatment outcomes, which in turn hampers the development of targeted therapies and effective healthcare planning.

The comprehensive report titled “Hypercalcemia - Market Insights, Epidemiology, and Market Forecast - 2034” offers a detailed analysis of hypercalcemia. The report presents historical and projected epidemiological data covering total incident cases of selected cancer, total incident cases of hypercalcemia among cancer, gender-specific incident cases of hypercalcemia, etiology-specific incident cases of hypercalcemia and total treated cases of hypercalcemia. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in hypercalcemia. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Hypercalcemia Overview

Hypercalcemia is characterized by elevated levels of calcium in the blood, which can cause a range of symptoms including fatigue, weakness, nausea, confusion, and in severe cases, cardiac arrhythmias or kidney complications. It is most commonly associated with underlying medical conditions such as malignancies or certain endocrine disorders but can also result from medication effects or vitamin imbalances. The severity of hypercalcemia varies widely, from mild and asymptomatic to life-threatening. It can develop gradually or suddenly, depending on the cause. While the precise pathophysiology depends on the underlying condition, dysregulation of calcium metabolism and abnormal parathyroid hormone activity are central factors. Prompt diagnosis and management are critical, especially in cases with severe symptoms or rapid onset, and unexplained hypercalcemia should prompt evaluation for secondary causes.

Hypercalcemia Diagnosis and Treatment Overview

Hypercalcemia is diagnosed primarily through clinical evaluation, supported by detailed patient history and laboratory assessment of serum calcium and related markers. Definitive diagnosis relies on elevated calcium levels confirmed by blood tests, along with measurements of parathyroid hormone, vitamin D, and other relevant biomarkers to identify underlying causes such as malignancies, endocrine disorders, or medication effects. Additional imaging or tests may be conducted based on patient history and symptoms to rule out secondary causes like tumors or granulomatous diseases.

Treatment for hypercalcemia varies depending on severity and underlying etiology, with no single approach suitable for all patients. Management strategies focus on lowering serum calcium levels, alleviating symptoms, preventing complications, and addressing the root cause. Options include intravenous hydration, bisphosphonates, calcitonin, corticosteroids, and in some cases, dialysis. Long-term treatment requires close collaboration between patient and clinician, considering disease severity, comorbidities, and patient preferences. Supportive care, such as monitoring kidney function and electrolyte balance, along with lifestyle adjustments, may further aid in managing the condition and improving quality of life.

Hypercalcemia Epidemiology

The epidemiology section of the hypercalcemia market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the total incident cases of hypercalcemia among cancer, supported by relevant tables and graphs to provide a clear and concise understanding of the data. Additionally, the report discloses the assumptions made during the analysis, ensuring transparency in data interpretation and presentation. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• In the US, approximately 60% of hypercalcemia cases occur in females, while around 40% are reported in males, highlighting notable gender differences in disease incidence and the need for tailored approaches to management and care.
• In the US, the most common cause of hypercalcemia is humoral hypercalcemia, accounting for approximately 80% of cases, while osteolytic hypercalcemia represents the second most common cause, comprising about 20% of cases.
• In Italy, hypercalcemia incidence is 4.74% in-patient, highlighting the need for timely diagnosis and effective management.
• In Japan, more than 1 million new cancer cases occur each year, underscoring a considerable health burden and highlighting regional influences on cancer occurrence and care. Current gaps in hypercalcemia management include limited long-term treatment options, challenges in addressing underlying causes, and the need for therapies with improved safety and efficacy profiles.

Hypercalcemia Market Outlook

The hypercalcemia therapeutics market is further expected to increase by the major drivers, such as the rising incident population, technological advancements, and upcoming therapies in the forecast period (2025-2034).

Hypercalcemia is managed primarily through a combination of therapies aimed at rapidly lowering elevated calcium levels and addressing the underlying causes of the condition. Standard treatments include intravenous (IV) hydration to enhance renal calcium excretion, bisphosphonates to inhibit bone resorption, calcitonin for short-term calcium reduction, and corticosteroids in cases related to vitamin D mediated hypercalcemia. For patients with malignancy-associated hypercalcemia or endocrine disorders, targeted therapies focus on controlling the primary disease process to prevent recurrent calcium elevation. Supportive care is critical, involving close monitoring of kidney function, electrolyte balance, and cardiac status to minimize complications. Despite the variety of available treatments, management can be challenging due to varying patient responses and underlying etiologies, and no single therapy is universally effective. Ongoing research aims to develop novel agents and personalized approaches that provide more effective and safer long-term control of hypercalcemia. With continued scientific advances and clinical dedication, the future holds promise for improved outcomes and better quality of life for patients affected by this complex metabolic disorder. According to the publisher, the Hypercalcemia market in the 7MM is expected to change significantly during the forecast period (2025-2034).

Hypercalcemia Drug Chapters

Marketed Drugs

ORKEDIA (evocalcet): Kyowa Kirin/ Mitsubishi Tanabe Pharma

ORKEDIA is a novel small-molecule calcimimetic discovered by Mitsubishi Tanabe Pharma Corporation. Kyowa Kirin holds rights for its research, development, marketing, and manufacturing in Japan and select Asian regions under a 2008 license agreement. ORKEDIA offers a targeted treatment option for managing hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism.

• In December 2019, Japan granted partial change approval for ORKEDIA (evocalcet) to treat hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism who are ineligible for, or have relapsed following, parathyroidectomy.
• In March 2019, Japan’s Ministry of Health, Labor and Welfare (MHLW) designated ORKEDIA (evocalcet) as an Orphan Drug Designation (ODD) for treating hypercalcemia in patients with parathyroid carcinoma or primary hyperparathyroidism who were unable to undergo, or had relapsed after, parathyroidectomy.

Hypercalcemia Market Segmentation

The “Hypercalcemia - Market Insights, Epidemiology, and Market Forecast - 2034” report provides a detailed outlook of the current and future hypercalcemia market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Hypercalcemia Market Size by Countries

The hypercalcemia market size is assessed separately for various countries, including the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2024, the United States held a significant share of the overall 7MM (Seven Major Markets) hypercalcemia market, primarily attributed to the country’s higher incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Hypercalcemia Drugs Uptake

This section focuses on the sales uptake of potential hypercalcemia drugs that have recently been launched or are anticipated to be launched in the hypercalcemia market between 2020 and 2034. It estimates the market penetration of hypercalcemia drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the hypercalcemia market.

The emerging hypercalcemia therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the hypercalcemia market.

Hypercalcemia Market Access and Reimbursement

The “Hypercalcemia - Market Insights, Epidemiology, and Market Forecast - 2034” report provides a descriptive overview of the market access and reimbursement scenario of hypercalcemia. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current hypercalcemia market trends and to fill gaps in secondary findings, we interview KOLs’ and SMEs’ working in the hypercalcemia domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or hypercalcemia market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the hypercalcemia unmet needs.

Hypercalcemia: KOL Insights

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Vagelos College of Physicians and Surgeons, US; University Hospital Giessen, Germany; Paris Diderot University, France; University of Campania Regional University Hospital of Malaga, Spain; Norfolk and Norwich University Hospitals, UK; Keio University School of Medicine, Japan; among others.

As per KOLs from the US, “Hypercalcemia poses a significant clinical challenge due to its diverse underlying causes and variable symptom severity, profoundly impacting patient quality of life. Experts stress the need for targeted therapies that address the root causes, such as malignancy or endocrine disorders, rather than just symptom control. Leading voices also emphasize the importance of personalized treatment strategies tailored to individual patient profiles and comorbidities to optimize outcomes and minimize complications”.

As per KOLs from Spain, “Despite ongoing efforts, a significant unmet need persists for effective and well-tolerated treatments to manage hypercalcemia. Experts highlight the importance of early diagnosis, personalized medical strategies, and comprehensive supportive care to better address the complex clinical and quality-of-life challenges faced by patients”.

As per KOLs from Japan, “The relatively low reported incidence of hypercalcemia may reflect underdiagnoses and limited awareness of the condition. Specialists emphasize the need for improved screening and comprehensive management strategies to address the diverse clinical challenges and enhance patient outcomes across varied populations”.

Competitive Intelligence Analysis

We conduct a competitive and market intelligence analysis of the hypercalcemia. Market, utilizing various competitive intelligence tools such as SWOT analysis and market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Hypercalcemia Pipeline Development Activities

The report offers an analysis of therapeutic candidates in clinical stages and examines companies involved in developing targeted therapeutics for hypercalcemia. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging hypercalcemia therapies.

Hypercalcemia Report Insights

• Hypercalcemia Patient Population
• Therapeutic Approaches
• Hypercalcemia Market Size and Trends
• Hypercalcemia Market Opportunities
• Impact of Upcoming Therapies

Hypercalcemia Report Key Strengths

• 10 Years Forecast
• The 7MM Coverage
• Hypercalcemia Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Hypercalcemia Market

Hypercalcemia Report Assessment

• Hypercalcemia Current Treatment Practices
• Unmet Needs
• Hypercalcemia Product Profiles
• Hypercalcemia Market Attractiveness

Key Questions

• How common is hypercalcemia?
• What are the key findings of hypercalcemia epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for hypercalcemia?
• What are the disease risk, burden, and unmet needs of hypercalcemia?
• At what CAGR is the hypercalcemia market and its epidemiology is expected to grow in the 7MM during the forecast period (2025-2034)?
• How would the unmet needs impact the hypercalcemia market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of hypercalcemia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2025-2034)?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the hypercalcemia market.
• Insights on patient burden/incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of market access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of key opinion leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.